




Effects of Methylphenidate on Memory and 




Methylphenidate (MPH) is the most prescribed medicinal drug for people 
diagnosed with attention deficit/hyperactivity disorder. However, the off-label 
use by healthy adults has increased over the last year due to the potential 
beneficial effects on cognitive performance. It causes augmented 
catecholaminergic neurotransmission by blocking dopamine and 
norepinephrine’s reuptake mainly in prefrontal cortex and striatum. The aim of 
this review was to examine the effects of MPH on memory and attention in 
healthy adults. The results were ambiguous, however, MPH’s beneficial effects on 
memory were found more consistently than effects on attention. In addition, 
individuals whose baseline performance was lower than average benefitted more 
than others. Optimal dosing seems to be dependent on the task and cognitive 
domain tested. The controversy about cognitive enhancing drugs arises when 
taking side effects, as well as ethical aspects, into consideration. Common adverse 
effects are insomnia and appetite loss. In conclusion, despite the positive effects 
of MPH on memory and attention, the use of MPH as cognitive enhancer in 
healthy adults is not recommended based on the lack of longitudinal studies and 
the risks of adverse effects. MPH self-medication is not recommended. 
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INTRODUCTION  
Methylphenidate (MPH) primarily gets prescribed for attention-deficit/hyperactivity disorder 
symptoms, such as difficulty concentrating, impulsivity and hyperactivity (Leonard, McCartan, 
White & King, 2004). However, MPH is increasingly used as cognitive enhancer by healthy 
individuals, which is the topic of the present review. 
The most common way of MPH administration is oral which is delivered in a pill form. 
This then becomes absorbed through the intestinal tract, where MPH is partially deactivated by 
first-pass metabolism in the liver. After accessing the systemic blood circulation, the drug 
crosses the blood-brain barrier enabling its immediate effects on the neural networks. Other 
ways of administration would be an intravenous injection or inhalation which causes the direct 
entry of the substance into the brain. Due to a lack of first-pass metabolism and partial 
deactivation, these methods are considered as more dangerous as they lead to a more rapid onset 
of the drug’s actions and feelings of euphoria (Dubljević & Ryan, 2015).  
Dosing of MPH can be either weight-based (e.g. 0.5 mg/kg) or absolute (e.g. 18 mg). It 
has been estimated that the clinically efficacious dose ranges from 0.3 mg/kg to 1.0 mg/kg in 
children with ADHD (Leonard et al., 2004).  
The action of immediate-release MPH typically lasts for about 4 hours and works by 
causing a change in catecholaminergic activity of the brain. It is not untypical that children will 
continue to suffer from this disorder throughout adolescence and later into adulthood, however, 
symptoms that manifest most in adulthood are difficulties maintaining routines whereas 
hyperactivity becomes less salient (Leonard et al., 2004).  
Until now, the molecular mechanisms by which MPH often succeeds in improving 
symptoms associated with ADHD are not entirely understood (Urban & Gao, 2012). Early 
research on its mechanism of action hypothesises that MPH’s effect on dopamine (DA) in the 
brain is likely to be the primary mode for yielding a therapeutic effect in ADHD patients 
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(Challman & Lipsky, 2000). Positron emission tomography (PET) studies, such as the one 
conducted by Volkow and colleagues (2005) have identified the possible role of dopamine in 
MPH’s action by monitoring MPH’s concentration and its effects in regions of the human brain. 
It was found that methylphenidate inhibits the reuptake of DA by binding to dopamine 
transporters (DAT) causing an accumulation of extracellular dopamine which rises 
proportionally to MPH-induced blocking of transporters and the amount of DA release. Hence, 
dopaminergic neurotransmission gets magnified with a therapeutic dose of 0.5 mg/kg of MPH 
occupying about 60% of DAT. As dopamine is a neurotransmitter that stimulates corticostriatal 
signalling and weakens background signals in striatal cells, augmentation in dopaminergic 
activity is associated with increased motivation to accomplish the task, as well as enhanced 
stimuli salience (Volkow, Wang, Fowler & Ding, 2005).  
More recent studies have demonstrated that not only MPH’s effect on DA accumulation 
but also on norepinephrine (NE) seem to be important in its pharmacodynamics (i.e. effects on 
the brain). NE’s actions are amplified similarly by MPH inhibiting the transporters required for 
reuptake respectively. In comparison to the amount of blocked DAT, a standard clinical dose of 
0.5 mg/kg MPH was shown to reach up to 20% more occupancy in NE transporters (NET) (i.e. 
total of approximately 80% NET binding) (Hannestad et al., 2010). As noradrenergic 
transmission is stimulated by MPH inhibiting NE reuptake, it seems likely that in sensory areas 
of the brain, synaptic input becomes magnified. This could lead to improvements in ADHD 
symptoms, in which inaccurate sensory processing may be the cause of easy distractibility and 
hindered focussing on a target stimulus (Drouin, Wang & Waterhouse, 2007). Moreover, 
experimenting with MPH infusions in animals, Zhang et al. (2012) have found strong support for 
the prefrontal cortex (PFC) being one of the major sites MPH acts on. The PFC is known to play 
a crucial role in the regulation and maintenance of attention and is involved in complex 
cognition and memory. Hannestad et al. (2010) state that the PFC’s pyramidal cells are affected 
by even slight changes in extracellular norepinephrine and dopamine and that it is possible that 
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the beneficial effects of MPH occur predominantly there. It became evident that MPH’s 
therapeutic effects are most likely due to excessive amounts of DA binding to D2 receptors and 
NE binding to 2 receptors. However, whether a therapeutic effect occurring at a dose of 0.5 
mg/kg is more due to 60%-70% DAT blockage or 70%-80% NET occupancy remains speculative 
(Hannestad et al., 2010).  
By boosting motivation and sharpening attention through stimulating dopaminergic and 
noradrenergic neurotransmission, MPH was proven to be an effective medication for the 
majority of children and adults suffering from ADHD. In contrast, off-label use by healthy 
persons has been increasing over the recent years (Sahakian & Morein-Zamir, 2007). In the 
media, information about the number of people taking MPH non-medically is frequently 
inaccurate and overemphasized. Studies estimating prevalence rates on healthy people using 
prescription drugs for cognitive enhancement in general found a broad range from 
approximately 1% to 20%. A German study assessing prevalence among 1053 university students 
found that 2.2% have used MPH at least once in their lifetime (Franke, Bagusat, Rust, Engel, & 
Lieb, 2014). However, determining the true prevalence rates is difficult and existing literature is 
often vague (Dubljevic & Ryan, 2015).  
Taking into consideration the widespread and increasing trend of illicit MPH use, 
concern is arising regarding the adverse effects users could suffer, as well as other moral issues 
making enhancement of cognitive functioning with prescription stimulants such as MPH 
debatable. Cognitive functioning refers to a variety of separate categories including attention, 
memory, executive functions, perception, language and more (Nehlig, 2010). This review will 
solely focus on memory and attention, as these areas have been shown to be strongly related to 
performance in academia (Rabiner, Carrig, & Dogne, 2013; Dehn, 2011). The aim of this thesis is 
therefore to examine the effects of MPH on memory and attention in healthy adults. Moreover, 
it will take the disadvantages of MPH usage such as negative side effects on the body and moral 
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concerns into account before globally evaluating if the use of MPH as cognitive enhancer in 
healthy adults can be further recommended. 
 
 
EFFECTS ON COGNITIVE DOMAINS 
 
Attention 
Based on MPH’s proven enhancing effects on dopaminergic transmission and the assumption 
that dopamine is essential in goal-directed actions and stimuli salience, many researchers 
initially expected attention to be one of the cognitive domains MPH would have the greatest 
effect on (Linssen, Sambeth, Vuurman, & Riedel, 2014).  
Attention is “the focusing of our inner resources and state of consciousness” (Cohen, 
2014, p.3) and it can be subdivided in various categories including selective-, divided- and 
sustained attention. Due to the inability of the human brain to process all sensory stimuli we are 
confronted with at once, our attentional system allows us to narrow processing capacities 
appropriately to relevant properties of our environment while blending out the irrelevant 
details. Selective attention refers to the prioritising of some stimuli over others. A stimulus can 
draw an observer’s attention just by being outstanding from competing stimuli through e.g. 
visual features which refers to bottom-up attention. This can be distinguished from top-down 
attention which describes the act of willingly directing one’s focus on specific items (Katsuki & 
Constantinidis, 2013). Another subcategory of attention is called divided attention which 
describes paying attention to multiple items at the same time. Furthermore, vigilance or 
sustained attention refers to a prolonged reaction to the appropriate cue which is indicative for 
the participant’s maintenance of attention (Repantis, Schlattmann, Laisney & Heuser, 2010). 
Linssen and colleagues (2014) performed a review of the effects of single dose MPH on 
healthy participants across several cognitive domains. Of the 27 studies that measured 
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attention/vigilance, 29% of the studies were able to report significant findings with respect to 
MPH’s beneficial effects in healthy volunteers. This makes attention/vigilance the fourth 
affected domain of six that were examined. According to the authors, the tasks of this domain 
are frequently used in MPH studies for control purposes as a result of their presumable MPH 
sensitivity. Furthermore, these results should be interpreted with care because often, an 
attention task was not always tested as one but was divided in numerous separate 
measurements.  
Some researchers found the dose-response curve of MPH to have an inverted-U shape. 
This entails the largest response to the drug occurs with a moderate dose, while a lesser response 
is associated with minimal and maximal doses (Finke et al., 2010). Linssen and her colleagues 
stated that this curve possibly differs between the cognitive domains respectively. By examining 
low, moderate and high doses in separate studies, they were able to gain an understanding of 
the dose-response relationships for each cognitive domain. The researchers recognised that 
some studies might not have obtained significant results due to inappropriate dosages (Linssen 
et al., 2014).  
One study (del Campo, 2013) assessed individual differences in responding to MPH. This 
study distinguished low- and high baseline performers in a double-blind, placebo controlled 
cross-over design. 16 males with ADHD and 16 males without medical condition participated in 
two positron emission tomography (PET)- and one magnetic resonance imaging (MRI) scan 
while performing a sustained attention task under the influence of 0.5 mg/kg MPH or a placebo. 
Blood samples of the participants were also taken in order to ensure that they were tested within 
MPH’s effective window and to monitor plasma levels of MPH between participants. On the 
Rapid Visual Information Processing task, participants are instructed to respond to a target 
sequence of digits among a stream of single digits. Performance on the task was measured by 
the participant’s sensitivity (i.e. rate of correct responses). There was no main- or interaction 
effect for MPH found, meaning that all participants together, disregarding ADHD diagnosis or 
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MPH intake performed equally. However, after splitting subjects into low- and high-baseline 
performers it became evident that all low-performance subjects benefitted from drug intake 
whereas the high-performance group did not show any improvements. In addition, the 
researchers detected that the MPH low-baseline performance group exhibited low dopamine 
receptor availably in their left caudate nucleus before MPH intake. Interestingly, after a single 
MPH dose they showed an increase in midbrain dopamine levels as well as normalised dopamine 
levels in the left caudate in contrast to the other participants. Regarding the high-baseline 
performers, the authors explain that their consistent results may be attributable to the ceiling-
effect.  This means that high performers already had a superior baseline performance so that 
there might have been not enough room for large improvements after MPH intake. This result 
may also be explained by the inverted-U function in which high-performance subjects would 
already be at the optimum catecholamine level and thus do not perform better under the 
influence of MPH. From this study, it can be concluded that attentional deficits are likely to 
stem from deficient dopamine receptor availability in the midbrain and left caudate and that 
MPH supports compensation for this. Also, MPH effects seem to be identical among all low 
baseline performers, regardless of the presence of an ADHD diagnosis or not (del Campo et al., 
2013). 
A study conducted by Agay, Yechiam, Carmel, and Levkowitz (2014) also wanted to test 
if the baseline-dependent effects of MPH can be considered as normalised performance in which 
the poor performers become better and the high performers diminish to an average level. 
Alternatively, they proposed that a MPH evoked normalisation of performance could occur for 
inferior performers only while superior performers are not affected at all. Twenty adults with 
ADHD and a control group of 19 healthy individuals underwent two sessions of a rapid Go/No-
Go task. In this test the participants had to discriminate between target and non-target stimuli. 
Reaction time, accuracy over time and response time variability was acquired as an assessment 
of sustained attention. While some received a placebo on the first trial and approximately 0.28 
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mg/kg MPH on the second, others received MPH first and the placebo on the second session. In 
contrast to the outcome of the study by del Campo (2013) it turned out that MPH did have a 
positive effect on sustained attention in both groups of ADHD and control participants. 
Moreover, MPH-induced improvements were larger for participants with low-baseline 
performance, but not lower for people with high-baseline performance. These results add up to 
previous found evidence that MPH leads to normalisation of performance in attention tasks in 
people that initially showed low performance, but not in individuals with previous above 
average. As a possible explanation for this finding, the researchers propose that high performers, 
in contrast to low performers, may rely more on automatic processes while carrying out the task 
which then does not demand as much cognitive control. Therefore, dopamine and 
norepinephrine levels are not as relevant for performance and MPH does not lead to attenuated 
performance when these levels exceed the optimum (Agay. Yechiam, Carmel & Levkowitz, 2014).  
Another study that aimed at exploring the effects of MPH on sustained attention was 
conducted by Tomasi et al. (2011) who compared healthy people who received a 20 mg dose of 
MPH and healthy controls in a blocked visual attention task. In this task, participants had to 
covertly attend to moving balls on a computer screen until they stop and then compare a new 
set of balls to the initial set to decide if their positions match. Meanwhile, measurements of the 
participants’ functional MRI blood-oxygen-level dependent (BOLD) signals in the dorsal 
attention network and the default mode network in the brain were taken. The dorsal attention 
network is comprised of areas like the PFC and parietal regions and is known to exhibit increased 
activation in tasks requiring attention, whereas the default mode network (e.g. the post 
cingulate cortex and insula) is characterised by inhibited activation during these. Hence, the 
researchers expected that the MPH group (n=16) would show higher activation in the dorsal 
attention network and stronger deactivation of the default mode network in comparison to the 
control group (n=16) who did not receive MPH while performing an attention-demanding task. 
The results reflect their initial hypothesis which clearly demonstrates that MPH promotes 
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activation in the dorsal attention network. Nonetheless, no significant difference was found for 
task accuracy between the groups. Moreover, reaction times did not differ significantly. These 
results, however, must be seen in the light of the limitations that it was not controlled for 
placebo effects and as every participant yielded almost 100% accuracy, it is difficult to investigate 
the influence MPH might have had on the experimental group (Tomasi et al., 2011). 
But does a general MPH-induced increase in attention reflected by some of the results 
necessarily lead to increased attention to solely the target or could it also mean that attention is 
enhanced to the entirety of incoming information without specifically privileging the target? 
This was examined in a study conducted by ter Huurne et al. (2015). Their aim was to compare 
the accuracy and reaction time of 20 healthy adults in a visuospatial attention task under the 
influence of either 20 mg MPH or a placebo. In a computer task, detection of the target stimuli 
was accompanied by distractors of which some were categorised as “strong” because they had 
characteristics similar to the target and others as “weak” as they had no similarities with the 
target. The target stimuli were faces located at a previously cued position, whereas the strong 
distractors were faces located at the opposing visual hemifield. The weak distractor was a 
scrambled face in the hemifield that was not cued. Participants were asked to respond by 
pressing the button that corresponds to the sex of the target face. It was found that strong 
distractors caused longer reaction times and a decline in accuracy, relative to the weak 
distractor, in each condition. Moreover, the MPH group was more accurate, but they also had a 
longer reaction time than the placebo-group suggesting that they had reduced their speed in 
favour of accuracy. Discussing these results, the researchers asserted that accuracy might have 
been improved in the MPH group because MPH led to enhanced target-like stimuli processing 
which, in turn, enabled the subjects to improve in distinguishing the target from the distractor. 
Existing literature suggests that the PFC, a site which MPH was shown to act on the most, 
encodes incoming information categorically (Sreenivasan, Curtis, & D’Esposito, 2014). As the 
strong distractors in this study were comprised of similar features to the target they might have 
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gotten processed in a preferential way too. This could have provoked a slowed-down decision-
making process and accordingly longer reaction times. Alternatively, ter Huurne and co-authors 
(2015) explained that the longer reaction times might be the result of lowered impulsivity in the 
healthy subjects, as MPH was proven to reduce impulsivity in people with ADHD. However, as 
MPH did not appear to have a main effect on reaction time this explanation is regarded as less 
probable. In conclusion, this study provided support for the enhancing distractibility effect of 
MPH due to increased processing of environmental stimuli. Nonetheless, there is a possibility 
that this is only the case if the distractor and target belong to the same category. Also, a further 
limitation may be that it was not controlled for blood plasma levels of MPH. Therefore, in this 
manner, it could not be guaranteed that testing occurred during the optimal time window and 
that variability of MPH blood levels between participants is not too large (ter Huurne et al., 
2015). 
In sum, the effects of MPH on attention in healthy adults seem to be controversial. While 
some studies found support for MPH enhancing attention by stimulating DA and NE 
neurotransmission, most of the empirical work has not found a general improvement in 
attention induced by MPH, but rather effects that only occur in a baseline- and dose-dependent 
manner. Thus, the largest improvements could be observed in individuals that showed a low 
baseline performance initially and it seems to be likely that medium-dosed MPH yields the most 
positive effects in healthy adults. 
 
Memory 
Research shows that dopaminergic neurotransmission in the PFC and striatum are related to 
working memory (Clatworthy et al., 2009) and dopamine is involved in retaining memories that 
are motivationally significant (Shohamy, Adcock, 2010). Consequently, it could be hypothesized 
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that elevated dopamine transmissions evoked by MPH intake could lead to improvement in 
memory. 
In the present, it is assumed that the human memory system consists of distinct, yet 
interactive systems (Nyberg et al., 2002). The process of creating a memory starts at the level of 
our sensory memory which receives and briefly stores information about the environment 
through bottom-up and top-down processes in perception. Sensory information of the stimulus 
enters our brain (i.e. bottom-up) and is recognised and analysed in the light of our expectations 
and contextual circumstances (i.e. top-down). In the working memory which has a large role in 
complex cognitive function, both recently acquired (i.e. short-term) and information retrieved 
from the long-term memory are held for processing during cognitive tasks (e.g. reasoning) 
(Baddeley, 1992). Short-term memory is marked by transient neuronal activity and information 
will eventually fade entirely if it is not given meaning or is rehearsed. This process of rehearsal 
or association with meaning is called consolidation and involves the strengthening of synapses 
over time which causes the memory to become a long-term memory (Lieberman, 2012). 
Repantis et al. (2010) conducted a systematic review of scientific literature that assessed 
the effects of MPH on several cognitive domains in a placebo-controlled manner. Memory was 
the only out of six domains in which performance of healthy subjects was significantly improved 
compared to the placebo. More specifically, the largest effect of MPH was observed in spatial 
working memory. For example, Mehta et al. (2000) conducted a within-subject study in which a 
PET scan was used in order to prove the hypothesis that healthy adults would benefit from 40 
mg MPH. In addition, it was hypothesized that, compared to the placebo session, they would 
exhibit greater changes in regional cerebral blood flow, compared to placebo, in parts of the 
frontal and parietal lobe which are typically involved in spatial memory. Before the memory task, 
baseline performance was examined for each participant using a digit span test. Then, 
participants performed a visual search computer task in which they had to touch multiple circles 
on the screen in order to see if they revealed a token or not. The aim was to find as many tokens 
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as possible and it was considered an error when a participant touched the same circle twice or 
touched a circle that hid a token in a previous trial. As expected, MPH led to a significant higher 
accuracy compared to placebo in the same participants. Additionally, imaging of the regional 
cerebral blood flow revealed that the blood flow in left dorsolateral prefrontal cortex and 
posterior parietal cortex was less in participants after MPH compared to placebo. It is possible 
that this attenuated blood flow is linked to more efficient activity in these particular brain areas 
and MPH’s known ability to enhance signal to noise ratio. Moreover, this study also found the 
baseline-dependent effect of MPH that could be observed in the attention studies, too (Mehta 
et al., 2000). It is important to note that this study recruited only ten male participants which 
may threaten the external validity of the results. Also, the authors underline that the other 
studies included in the systematic review by Repantis et al. (2010) disregarded that effects could 
be contingent upon baseline performances of the participants which may have contributed to 
inconsistent findings. Moreover, many studies used extremely low doses of MPH (10 mg - 20 mg) 
which is, under the assumption that the dose response curve follows an inverted-U shape, 
suboptimal for examining MPH’s effects. 
There are, however, also studies that found results that conflict with the notion of the 
inverted-U association between dosage and effects. Linssen et al. (2012) conducted a study in 
which 19 healthy male participants were tested on two memory related tasks amongst others 
while comparing the dose dependent effects of MPH in doses of 10, 20 or 40 mg with placebo. 
The testing phase consisted of four different testing days in which one of the four treatments 
was given to the participants in a random order. In one task, a word list had to be remembered 
by the participants and recalled both immediately and at a delayed point in time, followed by a 
recognition task. It was found that the doses 20 and 40 mg MPH affected the delayed recall of 
word lists positively while the 10 mg dose and immediate recall did not differ from placebo. Due 
to the observation that only the late recall was affected, it was concluded that MPH ameliorated 
memory consolidation. This was an expected finding as similar improvements on memory 
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consolidation have been found earlier after pharmacologically comparable amphetamine intake. 
As the observed dose-response relationship in this study was linear, these results pose a 
challenge for the notion of the inverted-U shaped function which may not be applicable to 
memory consolidation. A possible limiting factor might have been that the word list was not 
difficult enough and a ceiling effect occurred. Additionally, the participants performed equally 
on the spatial working memory task, regardless of the condition. The researchers state that this 
might be due to the time pressure the subjects experienced in this task which may have 
combined with the overall arousing effects of MPH to overarousal and, thus, impaired 
performance (Linssen et al., 2012). 
Two years later, the same research group collected data of more than 50 studies assessing 
the effects of MPH on memory in healthy adults (Linssen et al., 2014). It was found that, after 
MPH intake, working memory performance increased in 65% of all studies making it the 
cognitive domain MPH had the most effects on out of six domains examined. Out of all articles 
reviewed, performance increased in those studies employing a medium dose (10 mg – 20 mg or 
0.15 mg/kg –0.3 mg/kg), which adds to evidence of the existence of the inverted-U dose-response 
relationship in the domain working memory.  
The same review (Linssen et al., 2014) also looked at two other domains related to 
memory. These domains are “verbal learning and memory” and “visual learning and memory”. 
Verbal learning and memory deals with declarative memory and includes tasks like memorizing 
and recalling a pair of associated stimuli or word list learning. Interestingly, even within this 
category, the optimal dose seems to vary for different tasks as the performance on word list 
learning appears to improve with larger doses whereas the optimum in verbal paired associates 
tests is assumed to be medium. Significant results were found in 31% of the studies which 
supports the use of MPH in its positive effects in healthy adults. In contrast, none of the studies 
on visual learning and memory that were considered in this review reported a significant effect. 
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However, there was only a small number of studies integrated in this review which may explain 
the lack of evidence for effects in this category (Linssen et al., 2014). 
Another study brought further insight in the mechanism how MPH improves subjects’ 
performance on memory (Clatworthy et al., 2009). The authors described that the brain 
processes that are associated with working memory are dopaminergic transmissions from the 
midbrain to the striatum and PFC. Hence, the researchers expected that MPH induced a 
decreased dopamine receptor availability in these areas and that, based on this, it is possible to 
predict enhanced performance on a spatial working memory task in healthy volunteers. To test 
this, a double-blind placebo controlled study was carried out in which ten male subjects received 
either 60 mg MPH at the first occasion and a placebo at the second occasion or vice versa. 
Following the administration of MPH, their dopamine receptor availability was measured by the 
intravenous injection of [11C]-raclopride and a subsequent PET scan. [11C]-raclopride is a 
selective antagonist that acts at D2 receptors and can be labeled with a radioisotope for in-vitro 
imaging of the receptor blocking. This scan exhibits that the less receptors are occupied by [11C]-
raclopride the more extracellular dopamine must be bound to dopamine receptors. The results 
were in line with the expectations. MPH caused a decreased dopamine receptor availability in 
the ventral striatum during the working memory task and performance was simultaneously 
improved. A limitation in this study was the small number of participants which may threaten 
the generalizability of the findings. Furthermore, next to the placebo, only one dose of MPH 
could be tested. Therefore, the relationship between the response and different dosing could not 
be investigated (Clatworthy, 2009). 
According to the current literature, memory performance can be more improved by 
methylphenidate in healthy adults. Similar to attention, baseline performance plays an 
important role in so far as low baseline capacity individuals appear to profit more from MPH 
intake than others. Furthermore, it was observed that different dosages can have varying effects 
on the individual. While some studies found evidence for an inverted-U dose-response 
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relationship, others found contradictory evidence. The review by Linssen et al. (2014) showed 






The aim of this review was to investigate the effects of MPH on attention and memory in healthy 
adults. The evidence on the effects MPH has on both attention and memory, that was analyzed 
further, is controversial. For both cognitive domains, there are articles that support beneficial 
effects and others that did not.  
Studies on the drug’s effects on memory seem to be slightly more successful than studies 
on attention. MPH was shown to have positive effects on spatial working memory. These effects 
were also reflected in changes in regional blood flow that were associated with more efficient 
signal processing (Repantis, 2010; Clatworthy). Also, memory consolidation, as well as verbal 
learning and memory was improved by MPH intake (Linssen et al., 2012; Linssen et al., 2014). 
Most of the research MPH’s effects on attention concerned sustained attention. While 
some studies reported performance improvements under MPH, the review by Linssen et al. 
(2014) showed that the majority of studies assessing attention did not find significant results. In 
one study, MPH induced increased activation of the dorsal attention network as well as 
decreased activation in the default mode network. While it is established that activity in the 
former network is related to attention tasks, the latter is commonly less activated during tasks 
requiring attention. However, on the behavioral level, no differences between accuracy or 
reaction times between the MPH and the control condition were found in the visual attention 
task (Tomasi et al., 2011). Possible reasons for the lack of significant results in some studies can 
be attributed to the fact that they did not consider different dose-response relationships nor the 
baseline capacity of the individual. Many studies taking this into account were able to report a 
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significant performance improvement under MPH compared to placebo (e.g. Linssen et al., 2013; 
Agay et al., 2014). 
 Literature suggests that the off-label use of cognitive enhancers like MPH is rising, 
especially among students who believe in the drugs ability to improve concentration, alertness 
and academic performance (Cakic, 2009). Against this background, it is important to touch upon 
some implications the non-medical use of methylphenidate as cognitive enhancer has.  
Although MPH can have positive effects on memory and attention in healthy adults, it 
should be mentioned that MPH can also have negative adverse effects. These can be divided into 
multiple categories. First, cardiovascular problem, such as hypertension and tachycardia and 
angina can arise from methylphenidate intake (Freese, Signor, Machado, Ferigolo, & Barros, 
2012). The central nervous system may also be negatively affected, for example, it was discovered 
that MPH frequently causes insomnia and nervousness. In contrast to that, headache, dizziness 
and dyskinesia are considered to be less frequent side effects. As for the gastrointestinal (GI) 
system, it has been observed that there is a risk for anorexia and that this is one of the most 
prevailing adverse effects.  Nausea, abdominal pain and weight loss depict less severe GI 
symptoms caused by the consumption of MPH. Dermatologic problems induced by MPH 
administration are rather uncommon and include rash and urticaria (Challman & Lipsky, 2000). 
Moreover, it was detected that mental illnesses and behavioral tics are likely to become worse. 
However, Outram (2010) postulated that MPH’s side effects are rather mild and that most of 
them were not statistically significant in many studies. Additionally, the side effects that were 
significant were all of shorter and medium term and included primarily loss of appetite, dry 
mouth and moodiness and slight moodiness. Nonetheless, there is a lack of evidence on long-
term usage of MPH which might induce side effects in increased severity and number (Cakic, 
2009). As a result, the risks that are associated with MPH intake, as well as the missing 
information about adverse effects over a longer time period, do not outweigh possible positive 
effects healthy adults could experience.  
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Another issue regarding the use of MPH is the risk of dependence. Similar to cocaine 
which is a well-known addictive substance, MPH causes an accumulation of dopamine to build 
up by blocking DAT. Some researchers, like Heinz and colleagues (2012) argued that the increase 
in extracellular dopamine is a factor contributing to the addictive potential MPH has. Activities 
triggering a rewarding feeling like eating food or sex induce a DA increase of 50 – 100 %, 
compared to stimulants like MPH that lead to a 175 – 1000% rise (Heinz, Kipke, Heimann & 
Wiesing, 2012). Others argue that the speed at which DA concentration in the brain rises is more 
important in the development of an addiction. Compared to oral intake, MPH only creates a 
‘rush’ or a reinforcing feeling when its injected intravenously or inhaled, as research shows 
(Challman & Lipsky, 2000). Volkow et al. (1995) compared the effects of intravenously injected 
MPH to cocaine and found that both drugs act on the same brain areas. However, cocaine’s peak 
uptake was slightly quicker than MPH’s and cocaine’s clearance was faster. Two years later, 
Volkow and colleagues found a difference between the reinforcing effects of cocaine compared 
to MPH and that this difference emerges from the speed by which dopamine transporters are 
blocked instead of the time the blockage lasts for (Volkow et al., 1998). Thus, it can be said that 
MPH and cocaine differ in their pharmacokinetics. Nonetheless, Kroutil et al. (2006) stated that, 
in the United States 3.1% of people between 18 and 25 years of age taking ADHD drugs off-label 
are considered dependent, according to the criteria. The use of MPH is considered as especially 
dangerous if a family or history regarding substance abuse exists and its risk in inducing 
addiction should not be underestimated (Challmann & Lipsky, 2000). 
 
MPH as creating inequality? 
When people enhance their cognitive abilities with the help of pharmaceuticals like MPH they 
seem to have an advantage over people that do not, especially in competitive situations as 
examinations at university. According to a recent survey that asked over 3000 students in 
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Switzerland about their attitudes towards pharmaceutical cognitive enhancement, 80% of the 
people say it is unacceptable and unfair (Maier et. al, 2015). As cognitive enhancing drugs like 
MPH are not very cheap, they may be obtainable primarily for people with greater financial 
resources. Greely and colleagues (2008) pointed out this ethical concern using the analogy: 
cognitive enhancing is similar to “allowing some students taking a maths test to use a calculator 
while others must go without” (p.703), which most people would consider an unfair precondition. 
However, inequalities, that are due to genetic or environmental preconditions, in educational 
success already exist. Some individuals have the privilege to be able to go to a private school or a 
university with high tuition fees, while others do not. Also, genes play a role and may create 
favoured positions for some individuals. This way, academic success is not determined solely by 
how hard-working the student may be, but is also influenced by several other factors. But would 
taking MPH for enhancing cognitive abilities create even more inequality? Many studies that 
analyzed the effects of MPH on performance at cognitive task found a baseline-dependent effect. 
If it holds true that MPH benefits low ability individuals the most while not affecting high 
capacity individuals significantly, it would help students performing worse keeping up with 
others (Cakic, 2009). Nevertheless, there is still more research needed concerning which groups 
in particular show beneficial effects of MPH. 
 
Should use of MPH be encouraged or discouraged based on scientific 
evidence?  
The use of MPH holds potential to enhance cognitive performance in the fields of memory and 
attention. Some studies show that attention can be positively affected (del Campo et al, 2013; Agay 
et al., 2014, even though many studies could not support this (Linssen, 2014; Tomasi et al., 2011). 
A positive effect was most prominent when studies differentiated between low- and high- baseline 
performers and was mostly observed in low performers. Effects on memory were more consistent 
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as is reflected in the reviews by Repantis et al. (2010) and Linssen (2014) which found memory to 
be the most enhanced cognitive domain by MPH out of six. Furthermore, medium and high doses 
of MPH had positive effects on memory consolidation (Linssen et al., 2012). Risking MPH’s 
adverse effects and facing potential addictiveness for the purpose of self-enhancement instead of 
medical purposes may seem unacceptable for many. This in conjunction with numerous ethical 
questions one can debate about raises the question whether or not it should be encouraged for 
use outside of the medical domain. A libertarian perspective could be that, given a person is well 
aware of all potential harmful effects, they can decide freely if they want to use MPH for cognitive 
enhancement or not. On the other hand, possible adverse effects should be taken seriously. As 
MPH’s beneficial effects seem to be, to a great extent, limited to low-baseline performance 
individuals, it is difficult to estimate the degree of improvement, if any, that administration of the 
drug could lead to. In light of the negative implications associated with MPH including the 
conflicting scientific evidence, controversial ethical dilemmas and adverse effects, the use of 
MPH should be limited to use in a medical setting. 
 
Future research and Conclusion  
Future research is needed regarding the effects of MPH on healthy people’s cognition. More data 
have to be obtained on the effects of MPH on several cognitive domains such as attention, 
reasoning, problem solving and others while gaining more insight in individual differences, such 
as the baseline performance. Also, more research needs to be done on repeated doses MPH on 
cognition as most of the existing literature deals with single dose studies only. Research on long-
term effects after years of usage is still lacking. In addition to that, more research has to be done 
on the adverse effects and how they might be avoided or eliminated in the drug.  
Evidence on beneficial effects of MPH on cognitive abilities, like attention and memory 
are still somewhat ambiguous. Even if there is a considerable amount of studies showing 
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significant effects, they seem to depend highly on specifics of the task, individual differences and 
dosages most of the time. As appealing as the beneficial effects of MPH appear, potential adverse 
effects, like cerebrovascular-, sleep- and appetite problems should be taken seriously. Moreover, 
illicit stimulant abuse is also accompanied by ethical concerns. Two opposing positions are that 
MPH intake in competitive situations is seen as cheating and unfair while the other position 
postulates MPH is able to decrease inequalities. The beneficial effects of methylphenidate were 
shown to be greatest for underperforming participants which would mean that MPH intake 
could contribute to more equal opportunities among competing individuals. If the development 
of a cognitive enhancing drug that is safe and effective succeeds in the future, the debate about 
the legitimacy of using these drugs can be revisited. Awareness of the adverse effects should be 
raised and media should provide more deliberate information about MPH and other cognitive 
enhancers.  
In conclusion, MPH has the potential to increase performance in memory and attention. 
However, it has been shown that its positive effects are greatest when individuals have a low 
baseline performance. Against the background of side effects, potential for dependence and 
ethical conflicts, the use of MPH self-medication for cognitive enhancement is not 
recommended. Instead, medication intake should be supervised by clinical experts in order to 
safely handle appropriate doses and timing. 
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